A randomized-controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia

A randomized-controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia

Objective: Medication adherence is extremely important in preventing relapse and lowering symptoms in schizophrenic patients. However, estimates show that nearly half of these patients have poor adherence. The Brief Adherence Rating Scale (BARS) seems to be the most reliable tool assessing adherence...

Full description

Bibliographic Details
Main Authors:	Emmanuel eStip, Philippe D. Vincent, Catherine eGuevremont, Simon eZhornitsky, Constantin eTranulis, Juliette eSablier
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-08-01
Series:	Frontiers in Pharmacology
Subjects:	Compliance Schizophrenia antipsychotic MEMS adherence randomized
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00100/full

Similar Items

Genealogy of instruments for prodrome evaluation of psychosis
by: Jean-Gabriel eDaneault, et al.
Published: (2013-04-01)

Agenesis of corpus callosum and emotional information processing in schizophrenia
by: Emmanuel eStip, et al.
Published: (2012-02-01)

Internet addiction, Hikikomori syndrome, and the prodromal phase of psychosis
by: Emmanuel eStip, et al.
Published: (2016-03-01)

About the nature of contextual impairments revealed by FN400 abnormalities in schizophrenia
by: Fabrice eGuillaume, et al.
Published: (2013-03-01)

Subjective and objective cognitive dysfunction in schizophrenia- Is there a link?
by: Saffron eHomayoun, et al.
Published: (2011-07-01)

A study of theory of mind in paranoid schizophrenia: A theory or many theories?
by: Peter B. Scherzer, et al.
Published: (2012-11-01)

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review
by: Simon Zhornitsky, et al.
Published: (2012-01-01)

Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, pilot, case-control trial with quetiapine
by: Simon eZhornitsky, et al.
Published: (2011-05-01)

Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the mirror effect of schizophrenia
by: Joelle eDesfossés, et al.
Published: (2012-09-01)

Développement d'assistants technologiques cognitifs pour la schizophrénie : favoriser l’autonomie et l’adhésion au traitement
by: Sablier, Juliette
Published: (2010)

The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19
by: Emmanuel Stip, et al.
Published: (2020-12-01)

Relationships between Brain Structure and Metabolic Changes in Schizophrenia Patients Treated with Olanzapine: A Voxel-Based Morphometric Study
by: Genevieve Letourneau, et al.
Published: (2011-01-01)

Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia
by: Stéphane Potvin, et al.
Published: (2016-01-01)

Endocannabinoids and Schizophrenia
by: Stéphane Potvin, et al.
Published: (2010-10-01)

Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients
by: Dieter Naber, et al.
Published: (2009-10-01)

Changing the name of schizophrenia: patient perspectives and implications for DSM-V.
by: Constantin Tranulis, et al.
Published: (2013-01-01)

Bibliotherapy: Reading OVID During COVID
by: Emmanuel Stip, et al.
Published: (2020-12-01)

Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up
by: Chen-Chung Liu, et al.
Published: (2015-06-01)

Aproximación al concepto acidez.
by: Alexander Stip Martinez
Published: (2010-09-01)

Avaliação de caracteres morfologicos, de qualidade de sementes e suas correlações em hibridos ineditos de Panicum maximum jacq.
by: Paterniani, Ricardo Stip
Published: (1996)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in Cognitive Impairment in Schizophrenia. A virtual human patient trial using Quantitative Systems Pharmacology
by: Hugo eGeerts, et al.
Published: (2015-09-01)

Leukopenia Related to Haloperidol in a Case of Chronic Untreated Schizophrenia
by: Hrishikesh B Nachane, et al.
Published: (2021-01-01)

Physical activity in schizophrenia is higher in the first episode than in subsequent ones
by: Sebastian eWalther, et al.
Published: (2015-01-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

Desenvolvimento de uma metodologia para reconstrução tridimensional e analise de superficies do corpo humano
by: Paterniani, Paulo Ernesto Stip
Published: (2001)

Disaster management of the psychological impact of the COVID-19 pandemic
by: Mohamud Sheek-Hussein, et al.
Published: (2021-03-01)

Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors
by: Frederike eSchirmbeck, et al.
Published: (2013-08-01)

Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis
by: Kawtar El Abdellati, et al.
Published: (2020-10-01)

Patienters uppfattning av läkemedelsadministrering inom sluten psykiatrisk psykosvård
by: Höglund, Kristin
Published: (2012)

Correlates and Predictors of Medication Noncompliance in Patients with Schizophrenia
by: Duncan, Julianne Christine
Published: (1995)

THE APPLICATION OF THE CROSS COMPLIANCE IN DIRECT PAYMENTS TO FARMERS
by: Constantin DARIE
Published: (2014-12-01)

Progesterone and Cerebral Function during Emotion Processing in Men and Women with Schizophrenia
by: Julie Champagne, et al.
Published: (2012-01-01)

Sleep spindle deficits in antipsychotic-naïve early course schizophrenia and in non-psychotic first-degree relatives
by: Dara S Manoach, et al.
Published: (2014-10-01)

Microglial intracellular Ca2+ signaling as a target of antipsychotic actions for the treatment of schizophrenia
by: Yoshito eMizoguchi, et al.
Published: (2014-11-01)

Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2020-10-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Relationship between Brain-Derived Neurotrophic Factor and Schneiderian First Rank Symptoms in Antipsychotic-naïve Schizophrenia
by: Sunil eKalmady, et al.
Published: (2013-07-01)

Genetic pharmacotherapy as an early CNS drug development strategy: testing glutaminase inhibition for schizophrenia treatment in adult mice
by: Susana eMingote, et al.
Published: (2016-01-01)

Prion protein in myelin maintenance: what does the goat say?
by: Fredrik S Skedsmo, et al.
Published: (2021-01-01)

Treatment of early onset schizophrenia: Recent trends, challenges and future considerations
by: Nora S Vyas, et al.
Published: (2012-04-01)